Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| astrocyte | 13 studies | 34% ± 12% | |
| glutamatergic neuron | 6 studies | 35% ± 16% | |
| retinal ganglion cell | 4 studies | 42% ± 21% | |
| neuron | 3 studies | 27% ± 8% | |
| GABAergic neuron | 3 studies | 40% ± 2% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| brain | 6 studies | 25% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 17193.17 | 2631 / 2642 | 99% | 107.51 | 697 / 705 |
| eye | 0% | 0 | 0 / 0 | 99% | 39.56 | 79 / 80 |
| skin | 1% | 13.26 | 11 / 1809 | 87% | 44.32 | 409 / 472 |
| breast | 54% | 4002.39 | 248 / 459 | 31% | 4.53 | 347 / 1118 |
| ovary | 1% | 20.44 | 2 / 180 | 83% | 24.79 | 355 / 430 |
| thymus | 1% | 21.19 | 8 / 653 | 71% | 23.73 | 428 / 605 |
| adipose | 71% | 4483.89 | 860 / 1204 | 0% | 0 | 0 / 0 |
| kidney | 31% | 970.84 | 28 / 89 | 11% | 3.60 | 102 / 901 |
| adrenal gland | 0% | 10.79 | 1 / 258 | 36% | 6.63 | 83 / 230 |
| prostate | 1% | 22.17 | 3 / 245 | 16% | 1.60 | 82 / 502 |
| uterus | 0% | 0 | 0 / 170 | 16% | 3.53 | 75 / 459 |
| pancreas | 2% | 40.98 | 8 / 328 | 11% | 1.73 | 20 / 178 |
| muscle | 12% | 210.78 | 97 / 803 | 0% | 0 | 0 / 0 |
| lung | 0% | 0 | 0 / 578 | 9% | 1.05 | 100 / 1155 |
| stomach | 1% | 10.08 | 2 / 359 | 6% | 1.23 | 17 / 286 |
| bladder | 0% | 0 | 0 / 21 | 6% | 0.83 | 32 / 504 |
| esophagus | 0% | 3.59 | 2 / 1445 | 5% | 0.54 | 9 / 183 |
| liver | 0% | 0 | 0 / 226 | 4% | 0.81 | 18 / 406 |
| intestine | 0% | 20.02 | 4 / 966 | 3% | 0.41 | 17 / 527 |
| lymph node | 0% | 0 | 0 / 0 | 3% | 0.50 | 1 / 29 |
| blood vessel | 1% | 24.86 | 12 / 1335 | 0% | 0 | 0 / 0 |
| heart | 0% | 7.48 | 4 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0009066 | Biological process | aspartate family amino acid metabolic process |
| GO_0031966 | Cellular component | mitochondrial membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005759 | Cellular component | mitochondrial matrix |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0017188 | Molecular function | aspartate N-acetyltransferase activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | NAT8L |
| Protein name | N-acetylaspartate synthetase (NAA synthetase) (EC 2.3.1.17) (Camello-like protein 3) (N-acetyltransferase 8-like protein) |
| Synonyms | CML3 |
| Description | FUNCTION: Catalyzes the synthesis of N-acetylaspartate acid (NAA) from L-aspartate and acetyl-CoA . Promotes dopamine uptake by regulating TNF-alpha expression (By similarity). Attenuates methamphetamine-induced inhibition of dopamine uptake . . |
| Accessions | Q8N9F0 ENST00000423729.3 |
